Implications of applied research for prognosis and therapy of breast cancer.
Breast cancer is the one of leading causes of cancer-related deaths in women within economically developed regions of the world. The heterogeneity of the natural history of breast cancer complicates patient management in that there is tremendous variability in response to treatment and for survival. More recently, several biomarkers (hormone receptor status and HER2 expression) have been added to the risk evaluation and therapeutic assessments. Evolving knowledge of molecular biology and newer techniques, such as genomics and proteomics, offer the potential to better define the biologic nature of the disease process, both for risk and therapy. This review discusses classical as well as new prognostic and predictive techniques. These are leading to a paradigm shift from empirical treatment to an individually tailored approach, which may soon become a realistic option for patients, based on specific molecular profiles.
Barginear
M F
MF
Don Monti Division of Medical Oncology/Division of Hematology, North Shore University Hospital, New York University School of Medicine, United States.
Bradley
T
T
Shapira
I
I
Budman
D R
DR
D001943:Breast Neoplasms / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D040901:Proteomics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D046888:Tissue Array Analysis